Form 8-K - Current report:
SEC Accession No. 0001104659-25-001869
Filing Date
2025-01-08
Accepted
2025-01-08 07:45:22
Documents
16
Period of Report
2025-01-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm252221d1_8k.htm   iXBRL 8-K 30099
2 EXHIBIT 10.1 tm252221d1_ex10-1.htm EX-10.1 15025
3 EXHIBIT 10.2 tm252221d1_ex10-2.htm EX-10.2 15110
4 EXHIBIT 10.3 tm252221d1_ex10-3.htm EX-10.3 15734
  Complete submission text file 0001104659-25-001869.txt   261195

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA btai-20250107.xsd EX-101.SCH 3048
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20250107_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20250107_pre.xml EX-101.PRE 22381
18 EXTRACTED XBRL INSTANCE DOCUMENT tm252221d1_8k_htm.xml XML 3562
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 25516596
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)